EICHORCondition: Cardiovascular Disease · Sponsor: Amgen
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in subjects with elevated plasma Lipoprotein(a) \[Lp(a)\]. AMG 890 will be evaluated in approximately 80 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Men and women with ages between 18 and 70 years old, inclusive. * Protocol-defined elevated plasma Lp(a) level. * Body mass index (BMI) greater than or equal to 18 and less than or equal to 40 kg/m2, at screening. * Women must be of non-reproductive potential. * Other Inclusion criteria may apply Exclusion Criteria: * Currently receiving treatment in another investigational device or drug study. * Women who are lactating/breastfeeding or who plan to breastfeed while on study or through 90 days after receiving the last dose of investigational product (for subjects who withdraw prior to end of study). * History or evidence of a clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion. * History or clinical evidence of bleeding diathesis or any coagulation disorder. * History or clinical evidence of peripheral neuropathy. * Other Exclusion criteria may apply
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Orange County Research Center | Tustin, California, United States | — |
| Excel Medical Clinical Trials | Boca Raton, Florida, United States | — |
| Jacksonville Center for Clinical Research | Jacksonville, Florida, United States | — |
| QPS Miami Research Associates | South Miami, Florida, United States | — |
| University of Kansas Medical Center | Kansas City, Kansas, United States | — |
| New York University | New York, New York, United States | — |
| Medpace Inc | Cincinnati, Ohio, United States | — |
| Clinical Medical and Analytical eXellence CMAX | Adelaide, South Australia, Australia | — |
| Linear Clinical Research Limited | Nedlands, Western Australia, Australia | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03626662